- 1 Title: A Novel Association Between Human Papillomavirus and Thyroid Eye Disease
- 2 Authors: *Ishita Garg, BS¹, *Benjamin I. Meyer, MD², Ryan A. Gallo, PhD¹, Sara T. Wester,
- 3 MD FACS^{1,2,†}, Daniel Pelaez, PhD^{1,2,†}
- 4 *Co-first authorship, †Co-corresponding
- 5 Affiliations:
- 6 ¹Dr. Nasser Al-Rashid Orbital Vision Research Center, McKnight Vision Research Center, University of Miami
- 7 Miller School of Medicine, Miami, FL USA
- 8 ²Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine,
- 9 Miami, FL USA
- 10 Keywords: thyroid eye disease, human papillomavirus, autoimmune, ELISA, Graves' disease

11 Correspondence:

12	Daniel Pelaez, PhD
13	1638 NW 10 th Ave

14 Miami, FL 33136

16

15 <u>dpelaez@med.miami.edu</u>

Sara T. Wester, MD 900 NW 17th Street Miami, FL 33136 swester2@med.miami.edu

- 17 Acknowledgements/Funding: This work was supported in part by the Dr. Nasser Al-Rashid
- 18 Orbital Research Endowment (Miami, FL, USA). Bascom Palmer Eye Institute is supported by
- 19 NIH Center Core Grant P30EY014801 and a Research to Prevent Blindness Unrestricted Grant
- 20 (New York, NY, USA).
- 21 **Disclosures:** None.
- 22 Short Title: Thyroid Eye Disease and HPV
- **23 Word Count:** 2079
- 24 Data Availability: All datasets generated and analyzed during the current study are not publicly
- 25 available but are available from the corresponding author on reasonable request.
- 26 This work is original and has not been previously published.
- 27

28 ABSTRACT

Context: Thyroid eye disease (TED) is an autoimmune disease characterized by orbital 29 inflammation and tissue remodeling. TED pathogenesis is poorly understood but is linked to 30 31 autoantibodies to thyroid-stimulating hormone receptor (TSHR) and insulin-like growth factor 1 32 receptor (IGF-1R). 33 **Objective:** To explore the potential involvement of viral infections in TED pathogenesis. Methods: Using NCBI BLAST, we compared human TSHR and IGF-1R proteins to various 34 35 viral proteomes, including Papillomaviridae, Paramyxoviridae, Herpesviridae, Enterovirus, 36 Polyomaviridae, and Rhabdoviridae. Enzyme-linked immunoassays (ELISAs) were performed on orbital adipose tissue samples from 22 TED patients and controls to quantify antiviral 37 antibody titers. Demographics and clinical data were reviewed. 38 **Results:** Homology analysis revealed conserved motifs between TSHR and IGF-1R with several 39 viral proteins, particularly the human papillomavirus 18 (HPV18) L1 capsid protein. Basic 40 41 demographic and clinical information between the cohorts were comparable. ELISAs showed statistically significant differences in the average HPV18 L1 IgG normalized optical density 42 levels among tissues of control (M = 0.9387, SD = 0.3548), chronic TED (M = 2.305, SD =43 44 1.064), and active acute TED (M = 4.087, SD = 2.034) patients. These elevated HPV18 L1 IgG titers did not statistically correlate with TSH, T4, or TSI levels, and were elevated in TED 45 46 patients irrespective of treatment with teprotumumab, indicating a direct immunological response 47 to HPV. Conclusions: This study presents the first molecular evidence linking HPV and TED, 48

49 highlighting molecular mimicry between HPV capsid protein and key autoimmunity targets in

50 TED. This suggests an immunological link contributing to TED's pathogenesis, opening new51 avenues for understanding and managing the disease.

52

53 Introduction

54 Thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy or Grave's 55 orbitopathy, poses a unique clinical challenge for endocrinologists managing systemic thyroid disease. It is characterized by an intricate interplay of autoimmune mechanisms targeting orbital 56 57 tissues, resulting in debilitating symptoms such as proptosis, diplopia, pain, dry eyes, and redness 58 [1, 2]. In its most severe form, TED can lead to compressive optic neuropathy, potentially causing irreversible vision loss [3]. The incidence of TED in dysthyroid patients varies, ranging 59 from 25% to 50% of individuals with Graves' disease (GD) and approximately 3% to 5% of 60 those with Hashimoto's thyroiditis] [4, 5]. TED can also occur in euthyroid and, less commonly, 61 hypothyroid patients [2]. What predisposes an individual to develop TED and what leads to the 62 63 heterogeneity in clinical manifestations is largely unknown and a subject of significant clinical interest. A better understanding of risk factors for the development of TED in patients with 64 systemic thyroid dysfunction would enable better screening, risk modification, and improved 65 66 therapeutic management earlier in the disease.

TED is often classified into two distinct clinical phases: an active phase, marked by
vasodilation, orbital congestion, and inflammation, and an inactive phase characterized by
fibrosis and a potentially reduced responsiveness to therapeutic interventions [6]. The approval
of teprotumumab, a monoclonal antibody targeting the Insulin-like Growth Factor-1 Receptor
(IGF-1R), by the FDA in 2020 represented a significant advancement in TED management,
demonstrating the effectiveness of targeted biological treatments [7]. The phase 2 and phase 3

clinical trials for teprotumumab were conducted with patients with active, inflammatory TED,
however recent studies have shown that teprotumumab reduces proptosis in patients with noninflammatory TED as IGF-1R is overexpressed on fibroblasts in both the inflammatory and noninflammatory phases [8]. Despite this progress, ongoing clinical trials continue to investigate
various pharmacological agents designed to modulate the autoimmune and inflammatory
pathways implicated in TED, in pursuit of more comprehensive therapeutic options.

The persistent gaps in our understanding of TED's pathogenesis, especially regarding the factors influencing its onset and progression, underscore the necessity for further exploration into its underlying mechanisms. Although the majority of TED cases are related to GD, with documented upregulation of IGF-1R and Thyroid-Stimulating Hormone Receptor (TSHR) by autoantibodies, the occurrence of TED in patients without apparent thyroid dysfunction suggests that additional mechanisms beyond direct thyroid autoimmunity may be involved in its development [2, 3].

Emerging insights into the nature of autoimmune diseases have illuminated the potential 86 role of molecular mimicry, a process where external pathogens trigger autoimmune responses by 87 presenting antigens that resemble host tissues [9]. This concept introduces the hypothesis that 88 89 infections may act as catalysts for autoimmune conditions like TED through a process that is not yet fully understood, suggested by reports of new onset TED following COVID-19 infection 90 91 [10]. This study seeks to explore the hypothesis that an infectious agent may underlie the 92 pathogenesis of TED, leveraging mechanisms of molecular mimicry which then may initiate or exacerbate the disease process. 93

94

95 Materials and Methods

96 Homology Search

97 A protein homology analysis was conducted using the National Center for Biotechnology
98 Information (NCBI) Basic Local Alignment Search Tool (BLAST) to compare the human IGF99 1R isoform 1 precursor protein (NP_000866.1) and the human TSHR isoform 1 precursor protein
100 (NP_000360.2) with various viral proteomes.

101

102 *Participants and Specimen Collection*

The University of Miami Institutional Review Board approved this study (IRB
20110692). This study adhered to the tenets of the Declaration of Helsinki. Orbital adipose tissue
was collected from the medial fat of upper or lower eyelids in control patients undergoing
blepharoplasty or TED patients undergoing orbital decompression surgery at the Bascom Palmer
Eye Institute (Miami, FL). Eleven control patients and eleven patients with TED were included
in this study.

109

110 Orbital Adipose Sample Processing

Orbital adipose samples were cut into smaller sections and washed with 1X phosphate buffered saline (PBS). Orbital adipose samples weighing between 60 to 110 mg were used for downstream processing. To obtain protein lysates from the tissues, a Branson 450 Digital Sonifier was used at the following settings: a duty cycle of two seconds on/three seconds off for 40 seconds at 40% amplitude. The sample was then centrifuged for ten minutes at 14,000 x g and the supernatant was collected. Samples were stored in -80°C until further use.

117

118 Measurement of HPV18 L1 IgG

119	A detergent-compatible (DC) protein assay (Catalog # 5000112) was performed to
120	determine protein concentration in the processed samples. Protein concentrations were
121	normalized to the lowest concentration. Based on BLAST results, the Papillomavirus type 18 L1-
122	Capsid Antibody (IgG) enzyme-linked immunosorbent assay (ELISA; Catalog # NBP2-60106-
123	1Kit, RRID: AB_3095886) was performed to measure human papillomavirus 18 L1 capsid
124	protein (HPV18L1) IgG levels by optical density (OD) in control and TED patient samples.
125	Higher OD corresponded to increased light absorption by the sample, reflective of a higher
126	antibody antigen/antibody concentration. The protocol was followed as directed by the
127	manufacturer.
128	
129	Clinical Summary
130	Clinical data were extracted from patient records. Patient demographics and clinical
131	history were reviewed including age, gender, smoking status, thyroid-stimulating hormone
132	(TSH), thyroxine (T4), and thyroid-stimulating immunoglobulin (TSI) levels, and Clinical
133	Activity Score (CAS). The 7-point CAS scale was used.
134	
135	Statistical Analysis
136	To calculate the normalized OD (to account for the variable avidities, i.e. number of
137	binding sites, of different antibodies), the sample OD value was divided by the geometric mean
138	of the control samples as per ELISA manufacturer instructions. Statistical analyses were

139 computed using GraphPad Prism 10.0.2 (La Jolla, California). The one-way ANOVA with the

140 post-hoc Tukey test or unpaired T test were performed to identify differences between the means

141 of the study groups. Pearson correlation analyses with two-tailed p values were performed.

142

143 **Results**

144 Homology Between IGF-1R/TSHR and HPV Major L1 Capsid

145 BLAST homology analysis identified several homologous short sequences between

146 human IGF-1R and TSHR with various proteomic components within the following viral

147 proteome assemblies: Papillomaviridae, Paramyxoviridae, Herpesviridae, Enteroviruses,

148 Polyomaviridae, and Rhabdoviridae. There were many similarities between human IGF-1R and

149 TSHR with internal and viral matrix proteins, or to proteins encoded by the viral genome which

are expressed in the cytoplasm of infected host cells, which deprioritized these proteins as

151 significant antigenic triggers. However, there were homologous alignments between human IGF-

152 1R/TSHR with the major capsid proteins of the human *Papillomaviridae* family. Notably, two

153 motifs from the HPV L1 capsid protein were highly conserved across all human papillomavirus

serotypes and human IGF-1R and TSHR sequences: FGXV and IXEXT+NP (Fig. 1).

155

156 *Clinical Summary*

The demographic and clinical characteristics of the patient cohort are outlined in Table 1. 157 158 22 patients were included in this study (11 controls and 11 with TED). Acute disease activity was defined as CAS \geq 4 for less than 12 months; chronic disease was defined as lasting more than 12 159 160 months. Inactive disease was defined by patients with a CAS < 3. Of the patients with TED, 7 161 individuals had chronic disease and 4 individuals had acute active disease. Most patients were 162 female: 10 (10/11; 90.9%) in the control, 6 (6/7; 85.7%) in the chronic TED, and 3 (3/4; 75%) in 163 the acute active TED groups. Mean ages at the time of surgery were 63.02 years (range: 54-164 70.6), 52.66 years (range: 37.4-74.4), and 63.73 years (range: 49.4-69.8) for control, chronic

165 TED, and acute active TED patients, respectively. When comparing chronic versus acute active 166 TED patients, no statistically significant differences emerged in TSH (p = 0.6862), T4 (p =167 0.742), and TSI levels (p = 0.4931). The average highest CAS score for chronic TED patients

168 was 3 ± 2.236 while the average highest CAS score for acute active TED patients was $5.25 \pm$

169 0.9574.

170

171 Increased anti-HPV18 L1 IgG Titers in Chronic and Active TED Patients

172 Based on the results from the BLAST homology search, we next measured IgG antibody 173 titers against HPV18 L1 capsid protein by ELISA in orbital adipose tissue from the control and 174 TED patients. The mean normalized optical densities of human HPV18 L1 IgG antibody in the orbital adipose tissues were 0.9387 ± 0.3548 , 2.305 ± 1.064 , and 4.087 ± 2.034 from the control, 175 176 chronic TED, and acute active TED groups, respectively. These mean concentrations were 177 significantly different between control and chronic TED patients (p = 0.0344), control and active 178 acute TED patients (p = 0.0001), and chronic and active acute TED patients (p = 0.0333) (Fig. 179 2a). There was no significant evidence for correlations between orbital adipose tissue HPV18L1 180 IgG valency with TSH levels, T4 levels, or TSI levels in either chronic or acute active TED 181 patients (Fig. 2b; Table 2).

To parse out potential effects of teprotumumab intervention in TED patients on IgG HPV18 L1 valency, we performed subgroup analysis (**Fig. 2c**). No significant difference was noted comparing treated versus non-treated patients (Student T test). Further analyses did not reveal statistically significant differences between antibody titers in patients when comparing between radioactive iodine treatment or prior thyroidectomy (**Supplemental Fig 2**).

188 Discussion

This study presents molecular evidence suggesting a novel association between HPV and TED, facilitated potentially through molecular mimicry between the HPV's L1 capsid protein and significant autoimmunity targets in TED, specifically IGF-1R and TSHR. The discovery of significantly elevated IgG antibodies against the HPV L1 capsid protein in patients with chronic and active TED—irrespective of treatment with teprotumumab—highlights a potential immunological connection that may play a crucial role in TED's pathogenesis.

195 The *Papillomaviridae* family encompasses over 150 HPV subtypes, with types 16 and 18 196 being primary culprits in cervical cancers [11]. Molecular mimicry has been implicated in 197 various autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus 198 (SLE), Sjogren's syndrome, autoimmune liver disease, inflammatory bowel disease, and multiple 199 sclerosis [12]. This phenomenon has also been proposed to explain the rare occurrences of 200 autoimmune disease activation or flares following vaccination; however, such data are scarce and 201 sometimes conflicting, necessitating cautious interpretation to avoid potential confounders or the 202 mistaken extrapolation of correlation for causation [13-16].

The question of molecular mimicry's role in TED through HPV infection introduces a new dimension to this discussion. Research indicates that individuals with SLE not only show higher rates of high-risk HPV infections but also an increased risk of cervical dysplasia, likely due to immunosuppression [17, 18]. This suggests that an underlying autoimmune or inflammatory state may elevate HPV susceptibility. Moreover, a retrospective study of 62 patients highlighted a significant association between HPV infection and autoimmune disorders, with a 20% prevalence of autoimmune disease in HPV DNA-positive women versus approximately 3% in the general population, alongside increased autoantibody levels,

211 underscoring the complex link between HPV and autoimmunity [19].

212 The widespread vaccination against high-risk HPV strains, aimed at preventing cervical 213 cancer, has yielded substantial data for analysis, particularly in young women who are more 214 susceptible to autoimmune diseases due to hormonal changes during puberty [20]. Currently, 215 three HPV vaccines are in use: Cervarix (bivalent), Gardasil (quadrivalent), and Gardasil9 (nonavalent) [11]. A significant study by Jacobsen et al., involving nearly 190,000 vaccinated 216 217 young women, reported six new cases of Graves' disease post-vaccination with the quadrivalent 218 vaccine [21]. However, in a separate study this group found no pattern of autoimmune diseases 219 related to vaccine timing, dosage, or patient age, suggesting that the observed autoimmune 220 thyroid cases might have pre-existed vaccination, as indicated by a non-elevated incidence rate 221 ratio (IRR=0.72 [0.50-1.01]) upon detailed review [22].

The quadrivalent HPV vaccine, which leverages virus-like particles from the HPV L1 222 223 capsid protein, aims to replicate the HPV virus's structure to stimulate a suitable immune 224 response [23, 24]. Our findings show a homology between the HPV L1 capsid protein and key 225 TED autoimmunity targets (IGF-1R and TSHR), suggesting potential autoimmune disease 226 triggers from HPV L1 protein exposure or vaccination. Yet, prior extensive analyses, including a 227 systematic review and meta-analysis of over 169,000 autoimmune disorder cases, indicated no 228 significant risk increase for autoimmune diseases post-HPV vaccination (odds ratio 1.003) [25]. 229 This suggests HPV vaccination is safe and unlikely to directly initiate autoimmune disease, though it may reveal pre-existing autoimmune conditions, necessitating further research. These 230 231 insights highlight the need to differentiate the effects of natural HPV infection from vaccination

outcomes in TED research, ensuring that vaccine-induced autoimmunity is not mistakenlyimplicated or deduced.

The higher prevalence of both HPV and TED in females, contrasted with more severe disease manifestations in males, raises intriguing questions about sex-specific immune responses and hormonal influences on disease severity and progression [26]. This sex disparity could provide critical insights into the underlying mechanisms of HPV's impact on TED, highlighting an area ripe for further investigation.

239 Our study faces several limitations, including a small sample size and an imbalance in 240 male-to-female ratios (albeit reflective of natural demographic differences), which may affect the 241 generalizability of our findings. Additionally, the absence of detailed clinical histories regarding 242 prior HPV infection or vaccination status among participants limits our ability to fully 243 understand the relationship between HPV exposure and TED development. Despite these limitations, our findings offer a groundbreaking perspective on TED's 244 245 association with HPV through molecular mimicry, establishing a foundation for subsequent, 246 more definitive research. This exploratory study serves as a catalyst for future investigations to confirm the causative link between HPV and TED, potentially revolutionizing our approach in 247 248 managing this complex autoimmune condition.

249 **References:**

- 2501.Ugradar, S., et al., Teprotumumab for the treatment of chronic thyroid eye disease. Eye251(Lond), 2022. **36**(8): p. 1553-1559.
- Hoang, T.D., et al., 2022 Update on Clinical Management of Graves Disease and Thyroid
 Eye Disease. Endocrinol Metab Clin North Am, 2022. **51**(2): p. 287-304.
- Hodgson, N.M. and F. Rajaii, *Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review.* Ophthalmol Ther, 2020. 9(1): p.
 21-33.
- Bartalena, L. and M.L. Tanda, *Clinical practice. Graves' ophthalmopathy.* N Engl J Med,
 2009. **360**(10): p. 994-1001.
- Perros, P., et al., *Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.* Orphanet J Rare Dis, 2017. 12(1): p.
 72.
- Bothun, E.D., et al., *Update on thyroid eye disease and management*. Clin Ophthalmol,
 2009. **3**: p. 543-51.
- Fernando, R., O. Caldera, and T.J. Smith, *Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy*. Proc Natl Acad Sci U
 S A, 2021. **118**(52).
- 267 8. Ugradar, S., et al., *Teprotumumab for non-inflammatory thyroid eye disease (TED):*268 evidence for increased IGF-1R expression. Eye (Lond), 2021. **35**(9): p. 2607-2612.
- 269 9. Martins, Y.C., A.D. Jurberg, and C.T. Daniel-Ribeiro, *Visiting Molecular Mimicry Once*270 *More: Pathogenicity, Virulence, and Autoimmunity.* Microorganisms, 2023. 11(6).
- Allam, M.M., et al., *Thyroid disease and covid-19 infection: Case series*. Clin Case Rep,
 2021. 9(6): p. e04225.
- 11. Kombe Kombe, A.J., et al., *Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation.* Front Public Health,
 2020. 8: p. 552028.
- 12. Maoz-Segal, R. and P. Andrade, *Molecular Mimicry and Autoimmunity*. Infection and
 Autoimmunity, 2015: p. 6.
- Shan, J., et al., *COVID-19 vaccination and the risk of autoimmune diseases: a Mendelian randomization study.* Front Public Health, 2024. **12**: p. 1322140.
- 280 14. Kim, H.J., et al., Autoimmune adverse event following COVID-19 vaccination in Seoul,
 281 South Korea. J Allergy Clin Immunol, 2024.
- Acharya, I., et al., *Reactive Arthritis After mpox Vaccination*. J Community Hosp Intern
 Med Perspect, 2024. **14**(1): p. 35-38.
- 28416.Lim, S.H., et al., Autoimmune and Autoinflammatory Connective Tissue Disorders285Following COVID-19. JAMA Network Open, 2023. 6(10): p. e2336120-e2336120.
- 28617.Tam, L.S., et al., Natural history of cervical papilloma virus infection in systemic lupus287erythematosus a prospective cohort study. J Rheumatol, 2010. **37**(2): p. 330-40.
- Santana, I.U., et al., *Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review.* Clin Rheumatol, 2011.
 30(5): p. 665-72.

291	19.	Donmez, H.G., et al., Human papillomavirus infection and autoimmune disorders: a
292	20	tertiary center experience. Pathogens and Disease, 2019. 77(3).
293	20.	Desai, M.K. and R.D. Brinton, Autoimmune Disease in Women: Endocrine Transition and
294	21	Risk Across the Lifespan. Front Endocrinol (Lausanne), 2019. 10 : p. 265.
295	21.	Jacobsen, S.J., et al., An unmasking prenomenon in an observational post-licensure
290	22	Sujety study of adolescent girls and young women. vaccine, 2012. Su (S1). p. 4365-7.
297	22.	cialo, C., et al., surveinance of autoinmane conditions joilowing routine use of augdrivalent human nanillomavirus vassing. Untorn Mod. 2012. 271 (2): p. 192-202
290	23	Akuzum B et al. 11 Recombinant Proteins of HPV Tested for Antibody Forming Using
300	23.	Sera of HPV Quadrivalent Vaccine, Immune Netw, 2018, 18 (3): p. e19
301	24	CDC HPV Vaccine November 16 2021 [cited 2024 March 31]
302	25.	liang, Hv., et al., Human papillomavirus vaccination and the risk of autoimmune
303	201	disorders: A systematic review and meta-analysis. Vaccine. 2019. 37 (23): p. 3031-3039.
304	26.	Manji, N., et al., Influences of age, gender, smoking, and family history on autoimmune
305		<i>thyroid disease phenotype.</i> J Clin Endocrinol Metab, 2006. 91 (12): p. 4873-80.
306		
207		
307		
308		
309		
24.0		
310		
311		
312		
313		
314		
315		
316		
317		
210		
319		
319		
320		
		
321		





333 Figure 2a: Human papillomavirus 18 L1 capsid protein (HPV18L1) IgG levels orbital fat

334 samples. P value denoted by: * is ≤ 0.05 ; ** is ≤ 0.01 ; *** is ≤ 0.001 .

HPV18L1 lgG



- **Figure 2b: Subgroup analysis comparing thyroid status with HPV18L1 IgG levels.** TSH =
- thyroid stimulating hormone. Normalized OD₄₅₀ is the normalized optical density absorbability
- as the metric for antibody titer based on the enzyme-linked immunosorbent assay (ELISA)





343 Figure 2c: Impact of teprotumumab treatment on HPV18L1 IgG levels. Tepro =





	Control $(n = 11)$	Chronic TED (n = 7)	Acute Active TED (n = 4)
Age (Mean)	63.02	52.66	56.73
Range	54-70.6	37.4-74.4	49.4-69.8
Sex			
Female	10	6	3
Male	1	1	1
TSH		1.157 ± 1.538	0.8145 ± 0.6304
Free T4		1.396 ± 0.3023	1.46 ± 0.1510
Smoking			
Never	9	4	4
Former	1	3	0
Current	1	0	0
CAS			
Highest		3 ± 2.236	5.25 ± 0.9574
Range		1-7	4-6
HPV Valency	0.9387 ± 0.3548	2.305 ± 1.064	4.087 ± 2.034

359 Table 1: Patient Characteristics

360

361

362Table 2: HPV18L1 IgG Titer Subgroup Analysis

		Chronic TED (n = 7)		Acute Active TED (n = 4)	
		Correlation coefficient	P value	Correlation coefficient	P value
	TSH level	-0.5000	0.2667	0.8000	0.3333
	T4 level	0.2536	0.5832	-0.9617	0.1768
	TSI level	-0.6725	0.2136	-0.1543	0.9014
363					
364					

366 <u>Supplemental Figures:</u>

- 367 Supplemental Figure 1. Subgroup analysis of teprotumumab treatment and thyroid eye
- 368 disease status with HPV18L1 IgG levels.
- 369

HPV18L1 lgG



381 Supplemental Figure 2. Impact of thyroid treatment on HPV18L1 IgG levels.

